Sanofi Canada continues to spend money on trendy diabetes analysis to enhance outcomes for folks dwelling with diabetes

* Several Canadian research studies were presented at the American Diabetes Association’s 81st Annual Scientific Sessions to identify optimal therapies for sustainable diabetes management and remission.

LAVAL, QC, July 2, 2021 / CNW / – Building on a strong heritage and history in the diabetes field, Sanofi Canada attended the 81st Scientific Sessions hosted by the American Diabetes Association (ADA). The company featured several studies and research projects as part of its scientific leadership and commitment to helping people with diabetes get the best possible health outcomes.

Sanofi Canada (CNW Group / Sanofi Canada)

In addition to the SoliMix study, two Sanofi-funded research summaries based in Canada were presented, highlighting the importance of partnership and collaboration with the Canadian medical community and a global perspective in diabetes research.

“The world of diabetes is constantly changing, and so continuous research and intelligence from data is critical to improving patient outcomes,” said Sabina Steinkellner, General Manager, General Practice, Sanofi Canada. “Our commitment is to enable Canadians living with diabetes not only to easily and conveniently manage their disease, but to enjoy their lives to the full, which is supported by this type of research.”

Diabetes continues to have a high prevalence in Canada and globally, with diabetes currently affecting 10 percent of Canadians, with that number expected to climb to 12 percent by 2030.i

“Although a diagnosis of type 2 diabetes has always been viewed as permanent, recent studies have shown that both bariatric surgery and significant weight loss can achieve remission,” said Dr. Hertzel C. Gerstein, Professor of Medicine at McMaster University and Hamilton Health Science in Hamilton, Canada, and chair of the Diabetes Remission Research Program at the Population Health Research Institute. “The multi-center Canadian REMIT iGlar-Lixi study showed that three-month treatment with lifestyle therapy, coaching, metformin, and a fixed-ratio combination of lixisenatide and glargine achieved diabetes remission twice as safely as traditional approaches to diabetes used in diagnosed over the past five years, suggesting a promising direction for future research on the subject. “

The story goes on

Both Canada-led research projects were carried out with the support of several health centers across the country, including McMaster University, McGill University and other investigation sites; The aim was not only to study the treatment and control of diabetes, but also to achieve remission and simplify treatment in order to increase adherence. Further details on the two research projects funded by Sanofi can be found below.

REMIT iGlar-Lixi: Remission of type 2 diabetes after intensive treatment with insulin glargine, lixisenatide, metformin and lifestyle approaches: results of a multicenter randomized controlled studyii

• Main investigator: Natalia McInnes, MD, McMaster University & Hertzel Gerstein, MD, McMaster University To lead

• The aim of the study was to determine whether, in patients with early type 2 diabetes, short-term, intensive metabolic intervention with iGlarLixi, metformin and lifestyle approaches would be superior to standard diabetes therapy with regard to sustainable diabetes remission.

• Conclusion: A short-term intensive therapy for normoglycaemia and weight loss with insulin glargine / lixisenatide, metformin and changes in lifestyle can bring about a lasting remission of type 2 diabetes.

LixilanONE CAN: Randomized Study Comparing Daily vs. Weekly Titration Algorithm for Switching from Basal Insulin to iGlarLixi Fixed Ratio Combination in People with Type 2 Diabetes in Canadaiii

• Main investigator: Irene M. Hramiak, MD, FRCP (C), FACP

• The purpose of the study was to show that a simple daily titration algorithm is not inferior to the weekly titration algorithm according to the Canadian labeling.

• Conclusion: In this randomized study, a daily titration algorithm for iGlarLixi was demonstrated as a safe alternative to traditional weekly titration, allowing patients to reach their maintenance dose sooner.

More than 12,000 leading physicians, scientists, and healthcare professionals from around the world attended ADA’s scientific sessions to present cutting-edge research, treatment recommendations, and advances in curing diabetes.

Since the discovery of insulin 100 years ago, Sanofi has been a pioneer in insulin development. Through evidence-based discussions and the sharing of cutting-edge research, Sanofi aims to deliver simple, meaningful solutions to improve care for Canadians with diabetes.

About iGlar-Lixi
iGlarLixi is called SOLIQUA®. marketed Canada. SOLIQUA®, a fixed ratio combination of insulin glargine and lixisenatide, once daily injection, is indicated in combination with metformin as a supplement to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus who are inadequately controlled at: [PM p. 4A] Basal insulin (<60 units daily) alone or in combination with metformin, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) in combination with metformin.

About Sanofi Canada

Sanofi has set itself the goal of supporting people with their health challenges. We are a global biopharmaceutical company focused on human health. We prevent disease with vaccines, offer innovative treatments to reduce pain and alleviate suffering. We are among the few who suffer from rare diseases and the millions with long-term chronic illnesses.

With more than 100,000 employees in 100 countries, Sanofi transforms scientific innovations into healthcare solutions around the world. Sanofi companies in Canada employ approximately 2,000 people. In 2018, we invested more than $ 127 million in research and development in Canada, creating jobs, business and opportunities across the country.

Follow us on Twitter @SanofiCanada and on YouTube.

SOURCE Sanofi Canada

Cision

To download multimedia, see the original content: http://www.newswire.ca/en/releases/archive/July2021/02/c5142.html